Help ?

IGMIN: あなたがここにいてくれて嬉しいです. お願いクリック '新しいクエリを作成してください' 当ウェブサイトへの初めてのご訪問で、さらに情報が必要な場合は.

すでに私たちのネットワークのメンバーで、すでに提出した質問に関する進展を追跡する必要がある場合は, クリック '私のクエリに連れて行ってください.'

Abstract

要約 at IgMin Research

私たちの使命は、学際的な対話を促進し、広範な科学領域にわたる知識の進展を加速することです.

Medicine Group Case Report Article ID: igmin228

Levetiracetam-induced Rhabdomyolysis - A Rare Complication

Neurology Affiliation

Affiliation

    Section of Neurology, Department of Medicine, Aga Khan University, National Stadium Road, Karachi, Pakistan

Abstract

Background: Levetiracetam is an anti-epileptic drug that works by modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein 2A. Levetiracetam is generally well tolerated. Common side effects of levetiracetam include lethargy, drowsiness, headaches, and mood changes. Rhabdomyolysis and an increase in Creatine Kinase (CK) levels are one of the rarely reported effects of levetiracetam.
Case presentation: We present a case of a 20-year-old patient with previously known epilepsy (non-compliant with medicine) who presented with a seizure. The patient was given 1 gram of levetiracetam in the emergency department and was kept at a maintenance dose of 500 mg twice a day. The workup revealed acute kidney injury and raised levels of creatinine kinase that peaked at 19,757 IU/L 72 hours after levetiracetam was started. Levetiracetam was later switched to lamotrigine and aggressive intravenous hydration was done. Gradual improvement of CK level was noted accompanied by improvement in renal function.
Conclusion: Only a few cases of levetiracetam-induced rhabdomyolysis have been reported worldwide. Our case report highlights the importance of monitoring creatinine and CK levels while treating patients with levetiracetam as rhabdomyolysis can be asymptomatic with a rise in CK levels only.

Figures

References

    1. Moinuddin IA. Suspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review. Am J Case Rep. 2020 Oct 28;21:e926064. doi: 10.12659/AJCR.926064. PMID: 33112844; PMCID: PMC7603803.
    2. Tiglis M, Hurmuzache T, Bologa C, Neagu TP, Mirea L, Grintescu IM. Rhabdomyolysis-Induced Acute Renal Injury in a Schizophrenic Patient. J Crit Care Med (Targu Mures). 2020 Nov 7;6(4):249-252. doi: 10.2478/jccm-2020-0032. PMID: 33200097; PMCID: PMC7648442.
    3. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 Jul 2;361(1):62-72. doi: 10.1056/NEJMra0801327. Erratum in: N Engl J Med. 2011 May 19;364(20):1982. PMID: 19571284.
    4. Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015 Spring;15(1):58-69. PMID: 25829882; PMCID: PMC4365849.
    5. Shahbaz N, Younus SM, Khan SA, Ain Q-, Khan MA, Memon MH. Levetiracetam Induced Increase in Creatine Phosphokinase Levels. J Coll Physicians Surg Pak. 2017 Mar;27(3):S63-S64. PMID: 28302251.
    6. Akiyama H, Haga Y, Sasaki N, Yanagisawa T, Hasegawa Y. A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy Behav Case Rep. 2014 Sep 16;2:152-155. doi: 10.1016/j.ebcr.2014.08.001. PMID: 25667895; PMCID: PMC4308062.
    7. Al-Quliti K, Alhujeily RM. Acute kidney injury with levetiracetam in patient with epilepsy: a case report. Case Reports in Clinical Medicine. 2022;11(3):48-54.
    8. Di Lorenzo R, Li Y. Rhabdomyolysis associated with levetiracetam administration. Muscle Nerve. 2017 Jul;56(1):E1-E2. doi: 10.1002/mus.25548. Epub 2017 Mar 23. PMID: 28039868.
    9. Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008 Jun;4(3):507-523. doi: 10.2147/ndt.s2937. PMID: 18830435; PMCID: PMC2526377.
    10. Carnovale C, Gentili M, Antoniazzi S, Clementi E, Radice S. Levetiracetam-induced rhabdomyolysis: Analysis of reports from the Food and Drug Administration's Adverse Event Reporting System database. Muscle Nerve. 2017 Dec;56(6):E176-E178. doi: 10.1002/mus.25972. Epub 2017 Sep 30. PMID: 28888059.
    11. Kim H, Jo S, Park KW, Han SH, Lee SA. A Case of Phenytoin-induced Rhabdomyolysis in Status Epilepticus. J Epilepsy Res. 2016 Jun 30;6(1):36-38. doi: 10.14581/jer.16007. PMID: 27390679; PMCID: PMC4933680.
    12. Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J. 1993 May;69(811):333-336. doi: 10.1136/pgmj.69.811.333. PMID: 8393995; PMCID: PMC2399808.
    13. Gunathilake R, Boyce LE, Knight AT. Pregabalin-associated rhabdomyolysis. Med J Aust. 2013;199(9):624-625.
    14. Kazmi JS, Albarghouthy N, Ramsaywak R. Levetiracetam-Induced Rhabdomyolysis Reversed by Discontinuation: A Case Report. Cureus. 2023;15(11):e48955. doi: 10.7759/cureus.48955. PMID: 38111426; PMCID: PMC10726084.
    15. Nizamudeen K, Sabu ST, Dharan SS. An overview of the rare and life-threatening adverse effects of levetiracetam. World Journal of Pharmaceutical Research. 9:649-670. DOI: 10.20959/wjpr202011-18761

Similar Articles

Qualitative Model of Electrical Conductivity of Irradiated Semiconductor
Temur Pagava, Levan Chkhartishvili, Manana Beridze, Darejan Khocholava, Marina Shogiradze and Ramaz Esiava
DOI10.61927/igmin166